Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 02:00 ET | Source: Ontex

Ontex kondigt details aan voor de resultatenpublicatie van het 1ste kwartaal van 2026

Aalst, België, 13 april 2026 – Ontex Group NV, een toonaangevende internationale ontwikkelaar en producent van persoonlijke verzorgingsproducten, zal zijn resultaten van het eerste kwartaal van 2026...
April 13, 2026 02:00 ET | Source: NB Private Equity Partners Limited

NBPE Announces Transaction in Own Shares

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS NB...
April 13, 2026 02:00 ET | Source: Mothercare plc

Pre-close trading update

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE...
April 13, 2026 02:00 ET | Source: Alpha Growth PLC

Alpha Longevity Management launches U.S. specialty finance strategy for Japanese institutional investors, led by former members of Nikko Asset Management's team

REACH: non-regulatory announcement Alpha Growth plc("Alpha" or the "Company") Alpha Longevity Management launches U.S. specialty finance strategy for Japanese institutional investors, led by former...
April 13, 2026 02:00 ET | Source: Transgene S.A.

Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou

Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers
April 13, 2026 02:00 ET | Source: Transgene S.A.

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026 02:00 ET | Source: JLT Mobile Computers AB

JLT Mobile Computers AB (publ) släpper årsredovisning för 2025

Växjö, Sverige, 13:e april 2026 * * * JLT Mobile Computers, ledande leverantör av stryktåliga datorer för krävande miljöer, släpper idag sin årsredovisning för verksamhetsåret 2025. Periodens...
April 13, 2026 02:00 ET | Source: JLT Mobile Computers AB

JLT Mobile Computers AB (publ) Publishes 2025 Annual Report

Växjö, Sweden, April 13, 2026 * * * JLT Mobile Computers, a leading provider of rugged computers for demanding environments, publishes its 2025 annual report today. Report in brief Order intake SEK...
April 13, 2026 02:00 ET | Source: SynOx Therapeutics Limited

SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)

TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically...
April 13, 2026 02:00 ET | Source: Kenmare Resources

Notice of Annual General Meeting

Kenmare Resources plc(“Kenmare” or “the Company” or “the Group”) 13 April 2026 Notice of Annual General Meeting Kenmare Resources plc (LSE:KMR, ISE:KMR), one of the leading global producers of...